<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="352">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02218242</url>
  </required_header>
  <id_info>
    <org_study_id>13-LUN-95-MCC</org_study_id>
    <nct_id>NCT02218242</nct_id>
  </id_info>
  <brief_title>Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound</brief_title>
  <official_title>A Single-arm, Phase II Study of Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound at the Time of Definitive Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeremiah Martin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients undergoing video-assisted thoracoscopic (VATS) resection of lung cancer will
      receive standard therapy including lobectomy or sub-lobar resection and mediastinal lymph
      node dissection. After completion of the standard of care, intraoperative ultrasound will be
      used to evaluate lymph node stations for the presence of any missed lymph nodes with
      particular focus on lymph nodes which may appear pathologic on ultrasound evaluation. Data
      will be reviewed for rates of pathologic upstaging, and sensitivity and specificity of
      ultrasound as an additional diagnostic tool in the operating room will be evaluated. It is
      hyphothosized that Intra-operative thoracoscopic ultrasound following standard
      video-assisted thoracoscopic (VATS) dissection will increase the rate of pathologically
      staged in N2 nodes in non-small cell lung cancer patients undergoing definitive surgical
      resection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of detection of occult pathologic N2 lymph nodes</measure>
    <time_frame>At time of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraoperative ultrasound</intervention_name>
    <description>Intraoperative ultrasound</description>
    <arm_group_label>Ultrasound</arm_group_label>
    <other_name>B-K Medical/Analogic 8666-RF laparoscopic ultrasound transducer and the bedside flex Focus 1202 imaging system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age ≥18 years. ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). Life
        expectancy of greater than 3 months

        Patients be able to undergo VATS resection as defined below:

          -  Preoperative FEV1 ≥ 40% predicted

          -  OR

          -  Post-operative predicted FEV1 ≥ 0.8 l

          -  Hg ≥ 8.0

          -  No evidence of coronary ischemia on stress evaluation Ability to understand and the
             willingness to sign a written informed consent document.

        Exclusion Criteria:

        Patients with surgery for a prior ipsilateral lung cancer

        Patients with known brain metastases

        Uncontrolled intercurrent illness including, but not limited to, ongoing or active
        infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
        arrhythmia, or psychiatric illness/social situations that would limit compliance with
        study requirements. (Patients with HIV are not excluded from this study)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremiah Martin, MB BCh FRCSI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jermiah Martin, MB BCh FRCSI</last_name>
    <phone>859-323-6494</phone>
    <email>j.martin@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeremiah Martin, MB BCh FRCSI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 11, 2015</lastchanged_date>
  <firstreceived_date>August 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Jeremiah Martin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>Cancer</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Staging</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
